^
    Back
    Association details:
    Biomarker:KRAS G12D
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:MRTX1133 (KRAS G12D inhibitor) +
    amredobresib (BI 894999) (BET inhibitor) +
    dBET6 (BRD4 degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2022
    Title:

    LB079 / 4 - Pancreatic clonal replica tumors display functional heterogeneity in response to KRAS pharmacological inhibition and reveal unique epigenetic vulnerabilities to overcome resistance

    Published date:
    03/09/2022
    Excerpt:
    In this study we generated a KRASG12D-driven CRT xenograft model of pancreatic ductal adenocarcinoma and treated the CRTs with MEKi, SOSi, and MEKi + SOSi….Pharmacological combination of MEKi (trametinib) + SOS1i (BI-3406) or KRASG12Di (MRTX1133) with BETi (BI 894999 and dBET6) exhibited combination benefits in preclinical pancreatic cancer models.